The estimated Net Worth of Pharis Mohideen is at least $700 Thousand dollars as of 29 July 2024. Dr Mohideen owns over 1,785 units of DBV Technologies stock worth over $60,335 and over the last 6 years he sold DBVT stock worth over $13,911. In addition, he makes $625,260 as Chief Medical Officer at DBV Technologies.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dr Mohideen DBVT stock SEC Form 4 insiders trading
Dr has made over 4 trades of the DBV Technologies stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,785 units of DBVT stock worth $1,749 on 29 July 2024.
The largest trade he's ever made was selling 2,261 units of DBV Technologies stock on 29 July 2022 worth over $6,828. On average, Dr trades about 917 units every 91 days since 2018. As of 29 July 2024 he still owns at least 79,367 units of DBV Technologies stock.
You can see the complete history of Dr Mohideen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Pharis Mohideen biography
Dr. Pharis Mohideen is the Chief Medical Officer at DBV Technologies.
What is the salary of Dr Mohideen?
As the Chief Medical Officer of DBV Technologies, the total compensation of Dr Mohideen at DBV Technologies is $625,260. There are 1 executives at DBV Technologies getting paid more, with Daniel Tassé having the highest compensation of $1,103,012.
How old is Dr Mohideen?
Dr Mohideen is 56, he's been the Chief Medical Officer of DBV Technologies since . There are 1 older and 2 younger executives at DBV Technologies. The oldest executive at DBV Technologies is Daniel Tassé, 61, who is the CEO & Director.
What's Dr Mohideen's mailing address?
Pharis's mailing address filed with the SEC is C/O DBV TECHNOLOGIES S.A., 107, AVENUE DE LA REPUBLIQUE, CHATILLON, I0, 92320.
Insiders trading at DBV Technologies
Over the last 3 years, insiders at DBV Technologies have traded over $13,911 worth of DBV Technologies stock and bought 45,919 units worth $58,352 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Timothy E Morris, and Daniel B Soland. On average, DBV Technologies executives and independent directors trade stock every 91 days with the average trade being worth of $5,061. The most recent stock trade was executed by Pharis Mohideen on 29 July 2024, trading 1,785 units of DBVT stock currently worth $1,749.
What does DBV Technologies do?
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
What does DBV Technologies's logo look like?
Complete history of Dr Mohideen stock trades at DBV Technologies and Millendo Therapeutics
DBV Technologies executives and stock owners
DBV Technologies executives and other stock owners filed with the SEC include:
-
Daniel Tassé,
CEO & Director -
Dr. Pharis Mohideen,
Chief Medical Officer -
Sébastien Robitaille,
Chief Financial Officer -
Lucie Mondoulet,
Sr. VP & Deputy CSO -
Dr. Wence Agbotounou,
Chief Clinical Trial Officer & Sr. VP -
Caroline Daniere,
Chief HR Officer & Chief of Staff -
Joseph Becker,
VP of Global Corp. Communications -
Michele F. Robertson,
Chief Legal Officer -
Anne Pollak,
Head of Investor Relations -
Pascal Wotling,
Chief Technical Operations Officer -
Rosen Michel De,
Director -
Madduri Ravin Rao,
Director -
Viviane Monges,
Director -
Timothy E Morris,
Director -
Daniel B Soland,
Director -
Adora Ndu,
-
Pharis Mohideen,
Chief Medical Officer -
Sebastien Robitaille,
Chief Financial Officer -
Bros. Advisors Lp667, L.P.B...,
-
Virginie Boucinha,
Chief Financial Officer -
Daniel Tasse,
CHIEF EXECUTIVE OFFICER